Estimation of Second Primary Cancer Risk After Treatment with Radioactive Iodine for Differentiated Thyroid Carcinoma
- PMID: 27762670
- DOI: 10.1089/thy.2016.0266
Estimation of Second Primary Cancer Risk After Treatment with Radioactive Iodine for Differentiated Thyroid Carcinoma
Abstract
Background: An increase in the incidence of second primary cancers is the late effect of greatest concern that could occur in differentiated thyroid carcinoma (DTC) patients treated with radioactive iodine (RAI). The decision to treat a patient with RAI should therefore incorporate a careful risk-benefit analysis. The objective of this work was to adapt the risk-estimation models developed by the Biological Effects of Ionizing Radiation Committee to local epidemiological characteristics in order to assess the carcinogenesis risk from radiation in a population of Brazilian DTC patients treated with RAI. Absorbed radiation doses in critical organs were also estimated to determine whether they exceeded the thresholds for deterministic effects.
Methods: A total of 416 DTC patients treated with RAI were retrospectively studied. Four organs were selected for absorbed dose estimation and subsequent calculation of carcinogenic risk: the kidney, stomach, salivary glands, and bone marrow. Absorbed doses were calculated by dose factors (absorbed dose per unit activity administered) previously established and based on standard human models. The lifetime attributable risk (LAR) of incidence of cancer as a function of age, sex, and organ-specific dose was estimated, relating it to the activity of RAI administered in the initial treatment.
Results: The salivary glands received the greatest absorbed doses of radiation, followed by the stomach, kidney, and bone marrow. None of these, however, surpassed the threshold for deterministic effects for a single administration of RAI. Younger patients received the same level of absorbed dose in the critical organs as older patients did. The lifetime attributable risk for stomach cancer incidence was by far the highest, followed in descending order by salivary-gland cancer, leukemia, and kidney cancer.
Conclusion: RAI in a single administration is safe in terms of deterministic effects because even high-administered activities do not result in absorbed doses that exceed the thresholds for significant tissue reactions. The Biological Effects of Ionizing Radiation Committee mathematical models are a practical method of quantifying the risks of a second primary cancer, demonstrating a marked decrease in risk for younger patients with the administration of lower RAI activities and suggesting that only the smallest activities necessary to promote an effective ablation should be administered in low-risk DTC patients.
Keywords: estimation models; radiation carcinogenesis; radioactive iodine therapy; second primary cancer; thyroid cancer.
Similar articles
-
Increased risk of second primary malignancy in pediatric and young adult patients treated with radioactive iodine for differentiated thyroid cancer.Thyroid. 2015 Jun;25(6):681-7. doi: 10.1089/thy.2015.0067. Epub 2015 May 6. Thyroid. 2015. PMID: 25851829 Free PMC article.
-
Risk of second primary malignancy after radioactive iodine treatment for differentiated thyroid carcinoma.Ann Otol Rhinol Laryngol. 2006 Aug;115(8):607-10. doi: 10.1177/000348940611500806. Ann Otol Rhinol Laryngol. 2006. PMID: 16944659
-
Rising incidence of second cancers in patients with low-risk (T1N0) thyroid cancer who receive radioactive iodine therapy.Cancer. 2011 Oct 1;117(19):4439-46. doi: 10.1002/cncr.26070. Epub 2011 Mar 22. Cancer. 2011. PMID: 21432843 Free PMC article.
-
Well-differentiated thyroid carcinoma: the role of post-operative radioactive iodine administration.J Surg Oncol. 2013 May;107(6):665-72. doi: 10.1002/jso.23295. Epub 2012 Nov 28. J Surg Oncol. 2013. PMID: 23192391 Review.
-
Current controversies in the initial post-surgical radioactive iodine therapy for thyroid cancer: a narrative review.Endocr Relat Cancer. 2014;21(6):R473-84. doi: 10.1530/ERC-14-0286. Epub 2014 Oct 2. Endocr Relat Cancer. 2014. PMID: 25277792 Review.
Cited by
-
Age-Specific Risk of Second Primary Malignant Neoplasm After Radioactive Iodine Treatment for Differentiated Thyroid Cancer.JAMA Otolaryngol Head Neck Surg. 2025 Aug 21:e252626. doi: 10.1001/jamaoto.2025.2626. Online ahead of print. JAMA Otolaryngol Head Neck Surg. 2025. PMID: 40839358
-
Risk of Second Malignant Neoplasm in Familial Non-Medullary Thyroid Cancer Patients.Front Endocrinol (Lausanne). 2022 Mar 4;13:845954. doi: 10.3389/fendo.2022.845954. eCollection 2022. Front Endocrinol (Lausanne). 2022. PMID: 35311228 Free PMC article.
-
Multi-Omics and Management of Follicular Carcinoma of the Thyroid.Biomedicines. 2023 Apr 19;11(4):1217. doi: 10.3390/biomedicines11041217. Biomedicines. 2023. PMID: 37189835 Free PMC article. Review.
-
Radioactive iodine in differentiated thyroid cancer: a national database perspective.Endocr Relat Cancer. 2019 Oct;26(10):795-802. doi: 10.1530/ERC-19-0292. Endocr Relat Cancer. 2019. PMID: 31443087 Free PMC article.
-
Co-Occurrence of Differentiated Thyroid Cancer and Second Primary Malignancy: Correlation with Expression Profiles of Mismatch Repair Protein and Cell Cycle Regulators.Cancers (Basel). 2021 Oct 31;13(21):5486. doi: 10.3390/cancers13215486. Cancers (Basel). 2021. PMID: 34771648 Free PMC article.
MeSH terms
Substances
Supplementary concepts
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous